After restricting the matched cohorts to those who had at least 90 days of exposure to the index class drug, the heart failure hospitalization rate still remained lower for the SGLT2 cohort compared with the DPP4 cohort (61 patients, 1.7% in SGLT2 vs. 182 patients, 2.5% in DPP4) with aHR 0.74 (95% CI 0.55–0.98, p = 0.038; Additional file 6: Table S3). The gene discussed is SLC5A2; the disease is heart failure.